)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Anbio Biotechnology
Anbio Biotechnology (NNNN) investor relations material
Anbio Biotechnology Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary7 Apr, 2026
Executive summary
Revenue for 2025 was $8.65 million, up 5.6% from 2024, with gross profit of $7.54 million and net income of $6.40 million, reflecting a significant shift to non-COVID IVD products (80.4% of revenue in 2025).
Gross margin improved to 87.2% in 2025 from 71.9% in 2024, driven by a higher-margin product mix and cost controls.
The company completed its IPO in February 2025, raising $8 million in gross proceeds.
Operations are primarily conducted through a Samoa subsidiary, with a global sales footprint and a focus on regulatory compliance for IVD products.
Financial highlights
Revenue: $8.65M (2025), $8.19M (2024), $6.71M (2023); 2025 revenue up 5.6% YoY, 2024 up 21.9% YoY.
Gross profit: $7.54M (2025), $5.89M (2024), $3.36M (2023); gross margin rose to 87.2% in 2025.
Net income: $6.40M (2025), $2.37M (2024), $2.25M (2023); net income up 169.9% YoY in 2025.
SG&A expenses dropped 54% in 2025 due to lower professional fees post-IPO and cost controls.
R&D expenses decreased to $201K in 2025 as products matured and required less development.
Cash and equivalents at year-end 2025: $7.77M; working capital: $30.16M.
Outlook and guidance
Management expects continued growth in non-COVID IVD products and further market expansion.
Focus on regulatory approvals (IVDR in EU, FDA in US) and diversification into new diagnostic segments.
Sufficient cash and IPO proceeds to fund operations and expansion for at least 12 months.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Anbio Biotechnology
- Net income and gross margin rose despite lower revenue, driven by a shift to non-COVID diagnostics.NNNN
Q2 2025 - IPO targets global diagnostics growth, but faces customer concentration and dual-class risks.NNNNRegistration filing
- IPO targets $7M for global IVD expansion, with growth in non-COVID products and key governance risks.NNNNRegistration filing
- 2024 revenue rose 21.9% to $8.19M, with gross margin at 71.9% and net income of $2.37M.NNNNQ4 2024
- Planned IPO with recent capital raises, governance structures, and a waiver for financial statement timing.NNNNRegistration filing
- Proposed public offering features multi-class shares, audited financials, and emerging growth status.NNNNRegistration filing
Next Anbio Biotechnology earnings date
Q4 20267 Apr, 2027
Anbio Biotechnology
Next Anbio Biotechnology earnings date
Q4 20267 Apr, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)